No Data
KPC Pharmaceuticals Gets Approval for Post-Surgery Delirium Drug Trial
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
KPC Pharmaceuticals, Inc. (600422.SH): Gastrodin injection has received the Drug Clinical Trial Approval Notification.
On February 28, Gelonghui announced that KPC Pharmaceuticals, Inc. (600422.SH) recently received the clinical trial approval notice issued by the National Medical Products Administration for the Gastrodin injection classified as a Chemical Drug category 2.4 new drug, allowing related clinical trial research to proceed. This new drug is a category 2.4 new drug developed by the company, indicated for the prevention of postoperative delirium in cardiac surgery.
Are Investors Undervaluing KPC Pharmaceuticals,Inc. (SHSE:600422) By 39%?
Announcement of KPC on the 2024 Annual Results Report
KPC Pharmaceuticals Records 46% Higher Net Attributable Profit in 2024
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing
